Compare SOWG & MNOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SOWG | MNOV |
|---|---|---|
| Founded | 2010 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 63.4M | 67.9M |
| IPO Year | 2011 | 2004 |
| Metric | SOWG | MNOV |
|---|---|---|
| Price | $2.99 | $1.34 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $7.50 |
| AVG Volume (30 Days) | 17.2K | ★ 37.0K |
| Earning Date | 05-15-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $2,360,807.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $180.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 194.15 |
| 52 Week Low | $0.10 | $1.17 |
| 52 Week High | $4.45 | $1.96 |
| Indicator | SOWG | MNOV |
|---|---|---|
| Relative Strength Index (RSI) | 44.31 | 47.47 |
| Support Level | $0.38 | $1.30 |
| Resistance Level | $4.43 | $1.46 |
| Average True Range (ATR) | 0.27 | 0.04 |
| MACD | -0.12 | -0.00 |
| Stochastic Oscillator | 23.04 | 33.33 |
Sow Good Inc is engaged in manufacturing and marketing freeze-dried fruits, vegetables, snacks, smoothies, and soups. The company also sells gluten-free products under the Sow Good brand. The company is developing a freeze-dried candy market and snack manufacturing to provide consumers with flavorful freeze-dried treats. The company operates in one reportable segment, reflecting its capital-light business model under which it earns proceeds from the sale of freeze-dried candy products.
MediciNova Inc is a biopharmaceutical company developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States (U.S.) market. It is currently focused on developing MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and prevention of acute respiratory distress syndrome (ARDS); and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease (NAFLD), and hypertriglyceridemia.